Literature DB >> 26487587

PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy.

T Goldmann1, C Kugler2, N Reinmuth3, E Vollmer4, M Reck3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26487587     DOI： 10.1093/annonc/mdv510

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

1.  PD-L1 Status in Refractory Lymphomas.

Authors:  Semir Vranic; Nilanjan Ghosh; Jeffery Kimbrough; Nurija Bilalovic; Ryan Bender; David Arguello; Yvonne Veloso; Aida Dizdarevic; Zoran Gatalica
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

2.  Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression.

Authors:  Sebastian Marwitz; Swetlana Scheufele; Sven Perner; Martin Reck; Ole Ammerpohl; Torsten Goldmann
Journal:  Clin Epigenetics       Date:  2017-05-11       Impact factor: 6.551

3.  Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma.

Authors:  Li-Jie Ma; Fei-Ling Feng; Liang-Qing Dong; Zhao Zhang; Meng Duan; Long-Zi Liu; Jie-Yi Shi; Liu-Xiao Yang; Zhi-Chao Wang; Shu Zhang; Zhen-Bin Ding; Ai-Wu Ke; Ya Cao; Xiao-Ming Zhang; Jian Zhou; Jia Fan; Xiao-Ying Wang; Qiang Gao
Journal:  Theranostics       Date:  2018-11-10       Impact factor: 11.556

Review 4.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

5.  Biomimetic radiosensitizers unlock radiogenetics for local interstitial radiotherapy to activate systematic immune responses and resist tumor metastasis.

Authors:  Jiajia Zhang; Mengdie Yang; Xin Fan; Mengqin Zhu; Yuzhen Yin; Hongyan Li; Jie Chen; Shanshan Qin; Han Zhang; Kun Zhang; Fei Yu
Journal:  J Nanobiotechnology       Date:  2022-03-04       Impact factor: 10.435

Review 6.  Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.

Authors:  Ioannis Zerdes; Alexios Matikas; Jonas Bergh; George Z Rassidakis; Theodoros Foukakis
Journal:  Oncogene       Date:  2018-05-16       Impact factor: 9.867

7.  Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients.

Authors:  Anna Grenda; Paweł Krawczyk; Justyna Błach; Izabela Chmielewska; Tomasz Kubiatowski; Stanisław Kieszko; Kamila Wojas-Krawczyk; Tomasz Kucharczyk; Bożena Jarosz; Iwona Paśnik; Małgorzata Borowiec-Bar; Małgorzata Frąk; Robert Kieszko; Michał Szczyrek; Katarzyna Reszka; Kinga Krukowska; Agnieszka Kolak; Sławomir Mańdziuk; Dariusz Kowalski; Marek Sawicki; Daria Świniuch; Elżbieta Starosławska; Rodryg Ramlau; Justyna Szumiło; Maciej Krzakowski; Janusz Milanowski
Journal:  Front Oncol       Date:  2021-02-08       Impact factor: 6.244

8.  PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.

Authors:  Patrick Micke; Carina Strell; Torsten Goldmann; Sebastian Marwitz; Dörte Nitschkowski; Rosemarie Krupar; Max Backman; Hedvig Elfving; Viktoria Thurfjell; Amanda Lindberg; Hans Brunnström; Linnea La Fleur; Artur Mezheyeuski; Johanna Sofia Margareta Mattsson; Johan Botling
Journal:  Cancer Immunol Immunother       Date:  2021-02-12       Impact factor: 6.968
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.